Wave Life Sciences Reports Q3 2026 Financial Results and Clinical Pipeline Updates
Wave Life Sciences (WVE) reported third-quarter 2026 revenue of $13.2 million, a significant increase from $7.6 million in the prior year, driven largely by its collaboration with GSK. Despite the revenue growth, the company recorded a net loss of $61.9 million due to increased research and development investments aimed at advancing its RNA medicine pipeline. The company maintains a strong liquidity position with $431 million in cash and marketable securities, providing an operational runway into Q3 2028. Key clinical milestones are concentrated in the fourth quarter of 2026, including data readouts for WVE-007 monotherapy dosing, WVE-006 RestorAATion-2 updates, and a CTA submission for its PNPLA3 liver disease program (WVE-008).
Topics: cash runway clinical trials net loss R&D spending revenue growth